We believe the ability to decode these interactions represents one of the greatest opportunities for innovation in medical science.
Repertoire immune medicines full#
The company’s proprietary DECODE™ technology platform, developed by Repertoire scientists, provides a comprehensive understanding of the full repertoire of interactions between T cell receptors and their antigen targets. Repertoire’s strategy lies in understanding the immune synapse – the interaction between specific T cells and the corresponding antigen-presenting cells that dictate T cell activity. Repertoire Immune Medicines is a clinical-stage biotechnology company dedicated to creating treatments for diseases based on the power of the human T cell repertoire to eliminate cancer cells, target pathogens and regulate immune function.
Repertoire immune medicines drivers#
Repertoire intends to utilize these insights into key drivers that govern immune function to design and develop novel immune product candidates. In particular, the platform identifies T cell receptor-antigen pairs in the context of other important features of the immune synapse, such as T cell function and how these antigens are presented by molecules on antigen-presenting cells, known as major human leukocyte antigen, or HLA, molecules. The DECODE platform is a powerful discovery engine that characterizes essential elements of the immune synapse. "Repertoire’s DECODE technology also provides us with the potential to design targeted immunotherapies for vitiligo." We will be able to apply the proprietary technology in our DECODE platform to assess and potentially identify the key drivers of the dysregulated immune response underlying this autoimmune disease, specifically the T cells and the antigens that activate them," said Anthony Coyle, Ph.D., President, Research and Development, Repertoire Immune Medicines. "The deep expertise and clinical experience that the UMass Chan team has in the field of vitiligo makes this an ideal partnership for Repertoire. The opportunity to combine our expertise in vitiligo with Repertoire’s DECODE™ technology means that, for the first time, we may be able to advance from translational insight to novel, antigen-specific therapies." "We understand the role of the T cell but have not been able to identify the specific codes directing their function. One of the challenges to discovering new treatment options for vitiligo is the significant complexity of the immune system," said Dr. "In autoimmune diseases, the best therapeutic options typically act broadly to suppress the immune system, which can lead to other complications for patients. Harris, M.D., Ph.D., Chair and Professor of Dermatology and Director of the Vitiligo Clinic and Research Center. The research team at UMass Chan will be led by John E. The potential discovery of these immunogenic drivers of vitiligo could be used to develop antigen-specific therapeutic candidates for this disease.
today announced it has entered a sponsored research agreement with UMass Chan Medical School (UMass Chan) to identify the specific T cell and antigen pairs involved in causing the onset and progression of the autoimmune disease vitiligo.
Research collaboration will utilize Repertoire’s DECODE™ platform to identify specific T cell receptors and antigens causing onset and progression of autoimmune disease vitiligo, with goal of developing targeted immunotherapyĬAMBRIDGE, Mass., February 17, 2022-( BUSINESS WIRE)- Repertoire Immune Medicines, Inc.
0 kommentar(er)
